tirzepatide fda changes confirms shortage is still over, gives compounders a grace period Retatrutide vs Tirzepatide: The FDA's

These include: Severe injection site reactions with spreading redness, warmth, or swelling Rash or hives suggesting an allergic response Anaphylaxis (facial swelling, breathing difficulty, collapse) Skin changes associated with signs of pancreatitis (severe abdominal pain radiating to the back) Symptoms suggestive of thyroid tumours (neck mass, difficulty swallowing, persistent hoarseness, breathing difficulties) Rapidly spreading cellulitis at injection site or blistering/mucosal rash Persistent skin problems that significantly impact quality of life or psychological wellbeing Referral to a dermatologist may be appropriate for severe nodulocystic acne, acne with scarring or risk of scarring, failure of 12 weeks of appropriate therapy, significant psychological impact, or clinical features of hyperandrogenism (e.g., hirsutism, irregular menses)

What should you avoid while taking tirzepatide

This can temporarily increase appetite suppression and slow digestion further, which makes digestive symptoms temporarily more noticeable

Not roughly a month

These symptoms require prompt medical evaluation

In addition, participants will be monitored for depression, suicidal ideation, and behavior risk through mental health questionnaires (Patient Health Questionnaire9 [PHQ9] [28] and the ColumbiaSuicide Severity Rating Scale [CSSRS] [29, 30])